STALICLA SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD). STALICLA is on a unique mission to identify clinically actionable patient subgroups and develop tailored treatments for those most impaired by their symptoms. Its DEPI technology is the first platform specifically developed to enable precision medicine in complex NDDs. The platform integrates comprehensive metabolomics, whole-genome sequencing, RNA sequencing and its advanced HC match module to pair patient biological signatures with drug candidates. DEPI has reached clinical proof of concept with its first pipeline candidate, STP1, currently in clinical trials. STALICLA is advancing collaborative alliances with strategic third-party pipelines and is rapidly scaling its platform and clinical development activity to bring 2 phase 2 pipelines in the clinic in 2022. To date STALICLA has raised $ 27.4 million and will be closing its series B in Q1 2022. For more information visit: https://stalicla.com.
Location: Switzerland, Geneva
Employees: 11-50
Total raised: $27.81M
Founded date: 2017
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.06.2025 | - | $2.5M | - |
| 16.01.2024 | Series B | $17.4M | - |
| 05.02.2020 | - | $7.91M | - |
Mentions in press and media 24
| Date | Title | Description |
| 02.07.2025 | Addex Therapeutics leads Stalicla’s CHF 2 million round | STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders (NND). The company has established a clinically validated neuro precision development platform t... |
| 30.06.2025 | Stalicla Secures CHF 2M Financing | Stalicla, a Geneva, Switzerland-based clinical-stage biotech company developing precision medicine for neurodevelopmental and neuropsychiatric disorders, raised CHF 2M in funding. The round was led by Addex Therapeutics. The company intends... |
| 07.03.2025 | Another year, another record by female-led startups | The latest edition of the Swiss Venture Capital Report showed that 2024 was another weak year for the Swiss startup-ecosystem. For the first time, both the invested capital and the number of funding rounds have decreased. However, there ar... |
| 01.07.2024 | Three biotech companies report progress on the way to the market | The European Commission (EC) has approved Idorsia’s JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. Hypertension is one of the lea... |
| 16.05.2024 | Startups restructure executive roles | Corina Schaer is the new Chief Product Officer at Leg&Airy, the startup revolutionizing the field of orthopedic aids using state-of-the-art 3D printing and scanning technology combined with its design to create custom-made orthoses. Co... |
| 16.01.2024 | Stalicla Secures $17.4 Million in Series B Financing | |
| 16.01.2024 | Stalicla Raises $17.4M in Series B Financing | Stalicla, a Geneva, Switzerland-based clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, raised $17.4M in Series B funding. The round was led by SPRIM Global Inve... |
| 16.01.2024 | Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements | - |
| 16.01.2024 | Stalicla Secures $17.4 Million in Series B Financing | - |
| 16.01.2024 | Stalicla secures USD 17.4 million in Series B Funding for precision medicine in neuropsychiatric and neurological disorders | Stalicla secures USD 17.4 million in Series B Funding for precision medicine in neuropsychiatric and neurological disorders 16.01.2024 14:50, Rita Longobardi linkedIn facebook twitter instagram youtube --> Stalicla, a clinical-stage biop... |
Show more